Ref: FOI/00236/CMICB 22 February 2023

Your Request:

- 1) What are your current skin cancer patient clinical pathway guidelines e.g., from initial patient symptoms in a GP setting to specialist referral as well as treatment and follow-up procedures and protocol. Attached are two outdated CCG (Clinical Commissioning Group) pathway guidelines for reference.
- 2) Does your skin cancer pathway include remote patient-clinic interactions (as opposed to face-to-face interactions), Yes or No and if yes, elaborate what they are and what stage in the pathway they're used e.g., teledermatology (the use of digital photography to assess patient lesions) at the GP stage.
- 3) What were your latest skin cancer pathway guidelines in 2019/2020 prior to the COVID-19 pandemic (announced as a pandemic by WHO on 11 March 2020).

Our Response:

1) Across NHS Cheshire & Merseyside ICB, the following NICE Guidance along with the guidance issued by Cheshire & Merseyside Cancer Alliance are followed:

NICE Guidance:

(<u>https://www.nice.org.uk/guidance/ng12/chapter/Recommendations-organised-by-site-of-cancer#skin-cancers</u>)

Cheshire & Merseyside Cancer Alliance Guidance:

https://www.cmcanceralliance.nhs.uk/resources/introduction/cqcs/skin

- 2) Teledermatology is currently being implemented across the Cheshire & Merseyside ICB area as an option for GPs to use at point of referral.
- 3) Information not held. You may wish to redirect your request for this information to the Cheshire & Merseyside Cancer Alliance, who can be contacted via: ccf-tr.admin.cmca@nhs.net